文献速递腹部CTMR

肝细胞癌的免疫治疗:AJR专家小组叙述性综述

Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review.
PubMed 文献 · AJR Am J Roentgenol · 2022-05-04

本文综述肝细胞癌免疫治疗现状及影像学反应评估挑战。免疫检查点抑制剂联合其他系统或局部治疗在基于CT或MRI的标准化反应标准下应答改善最明显,但CT/MRI表现独特,传统RECIST、mRECIST及EASL标准适用受限;新标准iRECIST和imRECIST尚待验证。文末提供共识声明供放射科医生参考。

要点

  • 免疫治疗联合其他系统或局部治疗时,基于CT或MRI标准化反应标准的应答改善最明显。
  • 免疫检查点抑制剂在CT和MRI上产生独特表现,挑战RECIST、mRECIST及EASL标准的应用。
  • iRECIST和imRECIST用于评估免疫治疗反应或进展,但尚待验证。

核心结论

  • 免疫治疗改变了肝细胞癌治疗格局,使晚期肝细胞癌患者获得生存获益。
  • 免疫检查点抑制剂的CT和MRI表现独特,传统反应标准如RECIST、mRECIST和EASL标准应用受限。
  • iRECIST和imRECIST等新标准已开发用于评估免疫治疗反应或疾病进展,但尚待验证。

研究设计与样本

  • 本文为AJR专家小组叙述性综述,描述肝细胞癌免疫治疗现状并总结已发表研究结果。
  • 综述回顾支持免疫治疗应用的病理生物学机制,并报告免疫治疗单用或联合其他治疗时反应评估的现状。

关键影像表现/征象

  • 免疫检查点抑制剂治疗在CT和MRI上产生独特表现模式。

诊断标准与关键数值

  • 传统反应标准包括RECIST、修改版RECIST和欧洲肝病研究学会标准。
  • 免疫治疗相关新标准包括免疫相关RECIST(iRECIST)和免疫修改版RECIST(imRECIST),但尚待验证。

临床应用与阅片要点

  • 文末提供共识声明,告知放射科医生在肝细胞癌治疗模式快速变化时代的基本考量。

局限性

  • iRECIST和imRECIST等新标准尚待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The advent of immunotherapy for patients with hepatocellular carcinoma (HCC) has changed the treatment landscape and conferred a survival benefit on patients with advanced HCC, who typically have a very poor prognosis. The most pronounced improvements in response, as documented by standardized response criteria based on CT or MRI, have been achieved when immunotherapy is combined with other systemic or locoregional therapies. Immune checkpoint inhibitor treatments result in unique patterns on CT and MRI that challenge the application of conventional response criteria such as RECIST, modified RECIST, and European Association for the Study of the Liver criteria. Thus, newer criteria have been developed to gauge therapy response or disease progression for patients receiving immunotherapy, including immune-related RECIST (iRECIST) and immune-modified RECIST (imRECIST), though these remain unvalidated. In this review, we describe the current landscape of immunotherapeutic agents used for HCC, summarize the results of published studies, review the pathobiologic mechanisms that provide a rationale for the use of these agents, and report on the status of response assessment for immunotherapy either alone or in combination with other treatment options. Finally, consensus statements are provided to inform radiologists about essential considerations in the era of a rapidly changing treatment paradigm for patients with HCC.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Cannella R, Lewis S, da Fonseca L, et al. Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2022. PMID: 35506555. doi:10.2214/AJR.22.27633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。